These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 2645387)

  • 1. Homoharringtonine-induced hyperglycemia.
    Sylvester RK; Lobell M; Ogden W; Stewart JA
    J Clin Oncol; 1989 Mar; 7(3):392-5. PubMed ID: 2645387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia.
    Warrell RP; Coonley CJ; Gee TS
    J Clin Oncol; 1985 May; 3(5):617-21. PubMed ID: 3889229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homoharringtonine: a new treatment option for myeloid leukemia.
    Luo CY; Tang JY; Wang YP
    Hematology; 2004 Aug; 9(4):259-70. PubMed ID: 15621733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia.
    Feldman EJ; Seiter KP; Ahmed T; Baskind P; Arlin ZA
    Leukemia; 1996 Jan; 10(1):40-2. PubMed ID: 8558935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
    Quintás-Cardama A; Kantarjian H; Garcia-Manero G; O'Brien S; Faderl S; Estrov Z; Giles F; Murgo A; Ladie N; Verstovsek S; Cortes J
    Cancer; 2007 Jan; 109(2):248-55. PubMed ID: 17154172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies.
    Kantarjian H; O'Brien S; Jabbour E; Barnes G; Pathak A; Cortes J
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):13-21. PubMed ID: 25458084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: a phase II Illinois Cancer Council Study.
    Runge-Morris MA; Kies MS; Vokes E; Blough R; Weidner L; Knop R; Rowland K
    Invest New Drugs; 1989 Jul; 7(2-3):269-73. PubMed ID: 2793384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia.
    Kantarjian HM; Keating MJ; Walters RS; Koller CA; McCredie KB; Freireich EJ
    Cancer; 1989 Mar; 63(5):813-7. PubMed ID: 2914287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homoharringtonine: a phase I evaluation.
    Stewart JA; Krakoff IH
    Invest New Drugs; 1985; 3(3):279-86. PubMed ID: 4066221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New natural products in cancer chemotherapy.
    Slichenmyer WJ; Von Hoff DD
    J Clin Pharmacol; 1990 Sep; 30(9):770-88. PubMed ID: 1980498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homoharringtonine: history, current research, and future direction.
    Kantarjian HM; Talpaz M; Santini V; Murgo A; Cheson B; O'Brien SM
    Cancer; 2001 Sep; 92(6):1591-605. PubMed ID: 11745238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors.
    Feun LG; Savaraj N; Landy H; Levin H; Lampidis T
    J Neurooncol; 1990 Oct; 9(2):159-63. PubMed ID: 2175770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of Homoharringtonine for the treatment of children with refractory or recurrent acute myelogenous leukemia: a pediatric oncology group study.
    Bell BA; Chang MN; Weinstein HJ
    Med Pediatr Oncol; 2001 Aug; 37(2):103-7. PubMed ID: 11496347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of homoharringtonine administered as a 5-day continuous infusion.
    Coonley CJ; Warrell RP; Young CW
    Cancer Treat Rep; 1983; 67(7-8):693-6. PubMed ID: 6871884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homoharringtonine for the treatment of chronic myelogenous leukemia.
    Quintás-Cardama A; Cortes J
    Expert Opin Pharmacother; 2008 Apr; 9(6):1029-37. PubMed ID: 18377344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined harringtonine or homoharringtonine chemotherapy for acute nonlymphocytic leukemia in 25 children.
    Li YH; Guo SF; Zhou FY; Xu SZ; Zhang HL
    Chin Med J (Engl); 1983 Apr; 96(4):303-5. PubMed ID: 6413148
    [No Abstract]   [Full Text] [Related]  

  • 17. Homoharringtonine is safe and effective for patients with acute myelogenous leukemia.
    Feldman E; Arlin Z; Ahmed T; Mittelman A; Puccio C; Chun H; Cook P; Baskind P
    Leukemia; 1992 Nov; 6(11):1185-8. PubMed ID: 1434802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of homoharringtonine in dogs.
    Lu K; Savaraj N; Feun LG; Guo ZG; Umsawasdi T; Loo TL
    Cancer Chemother Pharmacol; 1988; 21(2):139-42. PubMed ID: 3349562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical investigation of homoharringtonine.
    Legha SS; Keating M; Picket S; Ajani JA; Ewer M; Bodey GP
    Cancer Treat Rep; 1984 Sep; 68(9):1085-91. PubMed ID: 6478448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia.
    Feldman E; Arlin Z; Ahmed T; Mittelman A; Puccio C; Chun H; Cook P; Baskind P
    Leukemia; 1992 Nov; 6(11):1189-91. PubMed ID: 1434803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.